
## **CLAIMS**:

- 1. A process for preparing of an extract from the plant *Murraya koenigii*, useful in the treatment of asthma, said process comprising the steps of pulverising plant materials obtained from plant *Murraya koenigii*, extracting the plant material with a solvent at ambient temperature, concentrating the extract by filtering and evaporating it under reduced pressure and lyophilizing the concentrate to obtain a lyophilized extract containing active principles of the plant *Murraya koenigii*.
- 2. A process as claimed in claim 1 wherein the plant materials are obtained from plant parts of *Murraya koenigii* selected from garden fresh leaves or leaves dried under shade.
- A process as claimed in claim 1 wherein the leaves are pulverized by conventional methods to get homogenized leaves.
- 4. A process as claimed in claim 1 wherein the plant materials are extracted with solvents selected from hydrocarbon solvents, chlorinated solvents, ester solvents, ketonic solvents, alcohols, water and buffers.
- A process as claimed in claim 4 wherein the solvents are selected from the group consisting of petroleum ether (BP 40 60°C), petroleum ether (60°C 80°C), benzene, pentane, hexane, chloroform, dichloromethane, carbon tetrachloride, diethyl ether, tetrahydrofuran, dioxane, acetone, cyclopentanone, ethyl acetate, ethyl formate, methanol, ethanol, n-butanol, water and buffers.
- 6. A process as claimed in claim I wherein the concentration of the extract is effected by filtering and evaporating the solvents under reduced pressure at a temperature range of  $20^{\circ}\text{C} 80^{\circ}\text{C}$  preferably at ambient temperature and lyophilizing the concentrate by conventional methods to obtain mixtures of the active factors.
- 7. A process as claimed in claim 1, where in the extract obtained from the plant *Murraya* koenigii comprises active principles which dark colored solids soluble in dimethylsulfoxide.
- 8. A process as claimed in claim 1, wherein the active principles obtained from the plant *Murraya koenigii* are biocompatible and non-toxic in nature.
- 9. A process as claimed in claim 1, wherein the pharmaceutical composition is used for inhibition of arachidonic acid oxidation.



A process as claimed in claim 1 wherein the active principles have four peak with retention time 3.37, 3.49, 4.0 and 5.69 in methanol as solvent at 254nm.


- 12. A process as claimed in claim 1 wherein the extraction process is carried out for a period ranging from 1 120 prs, preferably between 12 16 hrs.
- 13. Pharmaceutical composition useful in the treatment of asthma, said composition comprising an effective amount of extract obtained from the plant *Murraya koenigii* together with, or optionally associated with a pharmaceutically acceptable additive.
- 14. A composition as claimed in claim 13 wherein the additives comprise powder or extracts of plants selected from M. paniculate Linn, H. abelmoschus, T. ammi, S. aromaticum, A. vasica Nees, E. hirta, and M. koinegii.
- 15. A composition as claimed in claim 13 wherein the additives are present in the range of 80-100 mg of M. paniculate Linn, 40-60 mg of H. abelmoschus, 38-62 mg of T. ammi, 7-13 mg of S. aromaticum, 85 115 mg of A.vasica Nees and 90-110 mg of E hirta.
- 16. A composition as claimed in claim 13 comprising:

| M. paniculata Linn. (KAMINI) | Syn. M exotica | 90mg  |
|------------------------------|----------------|-------|
| H. abelmoschus<br>(JOWAN)    |                | 50mg  |
| T. ammi<br>(LAVANGA)         |                | 50mg  |
| S. aromaticum<br>(BASAK)     |                | 10mg  |
| A.vasica Nees<br>(PUSITOA)   |                | 100mg |
| E.hirta                      |                | 100mg |
| M. koinegii<br>(Suravi Neem) |                | 100mg |

Bry (2)

- 17. A composition as claimed in claim 13 wherein the extract of the plant M. koinegii is present in the range of 87-105 mg per dose.
- 18. A composition as claimed in claim 13 wherein the additives are preferably present in an amount 90 mg of *M. paniculate Linn*, 50 mg of *H. abelmoschus*, 50 mg of *T. ammi*, 10 mg of *S. aromaticum*, 100 mg of *A.vasica Nees*, 100 mg of *E hirta*, and 100 mg of *M. koinegii*. per pose.
- 19. A composition as claimed in claim 13 wherein the extract of the plant M. koinegii comprises active principles which are dark colored solids, soluble in dimethylsulfoxide.
- A composition as claimed in claim 13 wherein the active principles have R<sub>f</sub> values 0.73, 0.60, 034 and 0.14 in chloroform and methanol in the ratio 19:1 and R<sub>f</sub> values 0.60, 0.38, 024 and 0.15 in the chloroform.
- A composition as claimed in claim 13 having four peak with retention time 3.37, 3.49, 4.0 and 5.69 in methanol as solvent at 254nm.
- (22. A composition as claimed in claim 13 wherein the active principles obtained from the plant M. koinegii exhibit antioxidant property i.e. O<sub>2</sub> inhibition.
- A method for the treatment of asthma, said method comprising the steps of administering an effective amount of the composition as claimed in claim 13 to a subject in need thereof,
- A method as claimed in claim 23 wherein the lyophilized extract obtained from *Murraya Koenigii* is administered along with other conventional additives for the treatment of asthma.
- 25. A method as claimed in claim 23 wherein the mode of administration is oral for the treatment of mild or acute asthma.
- A method as claimed in claim 23 wherein the dosage level of the composition is in between 325-600 mg twice daily for the period ranging from 3 to 30 days.
- 27. A method as claimed in claim 23 wherein the dosage level is in between 325-600 mg twice daily for the period ranging from 3 to 15 days for mild asthmatic condition, and 15 30 days for acute asthmatic condition.
- 28. A method as claimed in claim 23, wherein the additives are selected from M. paniculate Linn, H. abelmoschus, T. anmi, S. aromaticum, A. vasica Nees, E hirta, and M. koinegii.

ent also



- 30. A method as claimed in claim 23, wherein the additives are preferably present in an amount 90 mg of M. paniculate Linn, 50 mg of H. abelmoschus, 50 mg of T. ammi, 10 mg of S. aromaticum, 100 mg of A.vasica Nees, 100 mg of E hirta, and 100 mg of M. koinegii. per dose.
- 31. A method as claimed in claim 23, wherein the additives M. paniculate Linn, H. abelmoschus, T. ammi, S. aromaticum, A.vasica Nees, E hirta, and M. koinegii are administered to include properties such as antidiahorial, antiseptic, carminative, stimulation, anti-cough, anti-bronchitis and nourishment.
- A method as claimed in claim 23, wherein the additives are obtained from:

  M. paniculate Linn (bark or root), H. abelmoschus from dried flower buds, T. ammi from leaves, S. aromaticum from whole plant A. vasica Nees from root, E hirta from bark, and M. koinegii from leaves.
- 33. An anti-oxidant composition for human beings and animals, said composition comprising a effective amount of extract obtained from the plant *Murraya Koenigii* together with or optionally, associated with pharmaceutically acceptable additives.
- 34. A composition as claimed in claim 33 wherein additives comprise powder or extracts of plants selected from M. paniculate Linn, H. abelmoschus, T. ammi, S. aromaticum, A. vasica Nees, E hirta, and M. koinegii.
- 35. A composition as claimed in claim 33, wherein the additives are present in a range of 80-100 mg of *M. paniculate Linn*, 40-60 mg of *H. abelmoschus*, 38-62 mg of *T.ammi*, 7-13 mg of *S. aromaticum*, 85-115 mg of *A. vasica Nees*, 90-110 mg of *E hirta*, and 87-105 mg of *M. koinegii*. per dose.
- 36. A composition as claimed in claim 33, where in the additives are preferably present in an amount 90 mg of *M. paniculate Linn*, 50 mg of *H. abelmoschus*, 50 mg of *T. ammi*, 10 mg of *S. aromaticum*, 100 mg of *A.vasica Nees*, 100 mg of *E hirta*, and 100 mg of *M. koinegii*. per dose.

- 37. A composition as claimed in claim 33, wherein the additives M. paniculate Linn, H. abelmoschus, T. anmi, S. aromaticum, A. vasica Nees, E hirta, and M. koinegii are added to provide properties namely, antidiahorial, antiseptic, carminative, stimulation, anticough, anti-bronchitis and nourishment, respectively.
  - A composition as claimed in claim 33, wherein the additives are selected from *M.* paniculate Linn, *H. abelmoschus*, *T. ammi*, *S. aromaticum*, *A.vasica Nees*, *E hirta*, and *M. koinegii* in the form of bark or root; seed; fruit; dried flower buds; leaves; whole plant; and root, bark, leaves, respectively.
- 39. Use of the extract trained from the plant Murraya koinegii for the treatment of asthma.
- 40. An anti-asthma agent obtained from the plant Murraya koinegii.

addaily